Navigation Links
SemBioSys announces first quarter 2008 financial and operational results
Date:5/9/2008

------------ ------------

26,682,870 31,295,699

------------ ------------

------------ ------------

SemBioSys Genetics Inc.

Consolidated Statements of Loss, Comprehensive Loss and Deficit

(Unaudited)

-------------------------------------------------------------------------

(expressed in Canadian dollars, except shares)

Three month period ended

March 31, March 31,

2008 2007

$ $

Revenue

Licensing fees 50,110 437,012

Contract research - 105,776

Product sales 159,917 -

------------ ------------

210,027 542,788

Expenses

Research and development 2,794,103 1,743,973

General and administration 1,395,275 1,023,711

Intellectual property costs 342,330 528,249

Business development 159,630 309,474

Sales and marketing 153,160 -

Cost of products sold 271,745 -

Stock-based compensation 179,903 179,050

Amortization 493,834 228,058

Cost recoveries (532,369) (69,107)


'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. SemBioSys receives milestone payments from AVAC Ltd.
2. SemBioSys initiates toxicology study for safflower-produced insulin
3. SemBioSys announces 2007 financial and operational results
4. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
5. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
6. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
7. SemBioSys signs option agreement for safflower-produced food ingredient
8. SemBioSys announces 2007 third quarter results
9. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
10. SemBioSys updates Apo AI development program
11. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 LayerBio is an MIT spin-off ... care. The National Eye Institute (NEI) at the National ... I SBIR grant to develop a drug-eluting intraocular lens ... common cause of vision loss in people over age ... to Dr. Ken Mandell, LayerBio’s Founder and CEO, "There ...
(Date:12/19/2014)... 2014 The empty capsules market ... ageing population and technological innovations in the empty ... are catalysing the growth of the empty capsules ... , Scope of Report , The report ... new entrants/smaller firms to gauge the pulse of ...
(Date:12/19/2014)... 2014 Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... chronic pain, announced the results of its annual general ... a transformational year in Relmada,s history and it set ... said Sergio Traversa , chief executive officer of ... key financial, human resource and clinical development objectives that ...
(Date:12/17/2014)... December 17, 2014 Ipsen Biopharmaceuticals, ... IPN; ADR: IPSEY), today announced that ... as Somatuline®) was approved by the U.S. Food ... gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with ... metastatic disease to improve progression-free survival (PFS). , ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... 2012  Barbara Walters, Kevin Bacon, Kyra Sedgwick, Wanda Sykes ... in the PBS series Finding Your Roots with ... scientific help of leading personal genetics company, 23andMe.  23andMe ... Your Roots and consulted with show producers to ...
... company Innovative Carbon Limited today announces that they will be ... Graphene, a sheet of carbon just one atom thick, has ... at Manchester University in 2004, for which the team was ... produce it commercially. To support this work the UK ...
... 2012 Arteriocyte, a leading biotechnology company with ... today approval from the Food and Drug Administration ... using its Magellan MAR01™ technology in the treatment ... (IDE 15013) allows Arteriocyte and its clinical partners ...
Cached Biology Technology:23andMe Provides the Science Behind PBS Series "Finding Your Roots with Henry Louis Gates, Jr." With Its Personal Genome Service® 223andMe Provides the Science Behind PBS Series "Finding Your Roots with Henry Louis Gates, Jr." With Its Personal Genome Service® 3UK company to demonstrate their commercially effective graphene production process 2Arteriocyte Receives FDA Approval to Initiate Compartment Syndrome Trial for Amputation Prevention Focused on Wounded Warriors 2Arteriocyte Receives FDA Approval to Initiate Compartment Syndrome Trial for Amputation Prevention Focused on Wounded Warriors 3
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
(Date:12/5/2014)... 2014  Tute Genomics, a leader in cloud-based solutions ... A1 funding led by UK-based Eurovestech. Peak Ventures and ... investment round. "We are at a pivotal ... sequencing and seeks new approaches for the diagnosis, treatment ... MD MBA, and CEO of Tute Genomics. "One of ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... University (Canada) have teamed up with genome researchers from ... bone samples from Siberia. The project also involved ... and researchers from Russia, the United Kingdom, France, and ... sequences from a woolly mammoth will be published on ...
... the first solid evidence that still "sharp" older brains store ... discovery is reported by a Johns Hopkins team in the ... prove to apply as well to human brains, it could ... therapies based on what healthy older brains are doing, rather ...
... Unscripted biochemical variations, or noise, leads to oscillations in ... have debated for decades the relative importance of nature ... behaves, and now UCSD scientists report that noise could ... , In a paper in Proceedings of the National ...
Cached Biology News:Scientists sequence DNA of woolly mammoth 2'Sharp' older brains are not the same as younger brains 2Phenotype is influenced by nature, nurture and noise 2
... HT is designed for extended ... HT is ideal for applications ... primer extension assays. The iEMS ... a one-cabinet model, allowing the ...
... Source: Pseudomonas atlantica Description: Beta-Agarase is ... fragments from low-melting-temperature agarose. Beta-Agarase digests ... Tested User Friendly Properties: Heat Inactivation: ... Da Optimum pH: 6.5 Purity: Tested ...
iEMS Thermal Microplate Holder...
Improve inventory management with stainless steel red cell canisters; ensure product safety with CO2 or LN2 backup systems. A complete solution for your blood banking needs....
Biology Products: